logo
ProjectForthcoming

Cellular immunoTHERapy modelling by exploitation of humanized OSSicles

The status, timeline and source of this project. A free account opens every field.

Source: EU Funding & Tenders Portal

Bones represent a privileged site for cancer initiation and metastasis. Yet, current in vitro and animal models fall short in accurately recapitulating bone-developing cancers. To address this, we developed the human ossicle (hOss) technology: the in vivo formation of miniaturized bone organs composed of patient-derived bone and marrow cells. By mimicking the patient’s bone microenvironment, hOss

Status
Prospective
Location
Sweden
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Cellular immunoTHERapy modelling by exploitation of humanized OSSicles

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Cellular immunoTHERapy modelling by exploitation of humanized OSSicles” is an infrastructure initiative, located in Sweden. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

forthcoming

Taiyo status

Prospective

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Bones represent a privileged site for cancer initiation and metastasis. Yet, current in vitro and animal models fall short in accurately recapitulating bone-developing cancers. To address this, we developed the human ossicle (hOss) technology: the in vivo formation of miniaturized bone organs composed of patient-derived bone and marrow cells. By mimicking the patient’s bone microenvironment, hOss offer a personalized model for studying bone-related cancers. To ensure reproducibility and standardization, we further developed OssiGel—a customized extracellular matrix that reliably supports robust hOss formation from patient-derived cells. This innovation paves the way for advanced therapy testing, particularly for cellular immunotherapies, which still rely heavily on mouse models despite their limited clinical predictive value. Here, we aim to validate hOss as a superior platform for assessing the efficacy of immunotherapies. Using OssiGel, we will generate hOss and evaluate therapeutic responses, directly comparing outcomes in tumors engrafted in mouse bones versus hOss. Our project addresses a critical need to understand how the human bone/bone marrow microenvironment shapes immunotherapy outcomes. It proposes the first in vivo personalized model for testing immunotherapies, offering insight into the variable clinical success of current strategies.

Location

Country

Sweden

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Article published date

2025-10-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project